title: Malignant transformation of infantile hemangioma to angiosarcoma: response to chemotherapy with bevacizumab.
abstract: We describe a child initially diagnosed with multi-focal infantile hemangioma (cutaneous, hepatic, pulmonary), a benign vascular lesion, which underwent malignant transformation to angiosarcoma. The use of anti-angiogenic agents, such as bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has been reported in adults with angiosarcoma. Treatment with chemotherapy (gemcitabine and docetaxel) and bevacizumab resulted in disease response with progression free survival of 12 months. This report describes the response to chemotherapy and bevacizumab in a child with angiosarcoma and highlights the potential for malignant transformation of benign vascular lesions and the need for careful monitoring.
authors.affiliation: Division of Pediatric Hematology/Oncology/Stem Cell Transplantation/Cancer Biology, Stanford University School of Medicine, Palo Alto, California.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Jeng
authors.forename: Beng
authors.initials: B
authors.lastname: Fuh
authors.forename: Julie
authors.initials: J
authors.lastname: Blatt
authors.forename: Anita
authors.initials: A
authors.lastname: Gupta
authors.forename: Arnold C
authors.initials: AC
authors.lastname: Merrow
authors.forename: Adrienne
authors.initials: A
authors.lastname: Hammill
authors.forename: Denise
authors.initials: D
authors.lastname: Adams
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D002471:Cell Transformation, Neoplastic; D006391:Hemangioma / Q000473:pathology*; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: KRAS L19F; angiosarcoma; bevacizumab; malignant transformation